Uploaded July 2024 | Updated November 2026, 10 hours ago
Mike was diagnosed with type 1 diabetes at the age of 10.
Since then, he has learned to manage his condition through careful monitoring of his devices and wearables; But, what would happen if Mike’s data could be used to help researchers understand and learn more about diabetes?
What impact could his data have on other individuals living with diabetes?
Randomised controlled trials are the cornerstone of evidence-based medicine.
At the same time, the digitisation of real-world data from devices, and electronic health records provides opportunities to demonstrate efficacy and safety of innovative technologies including drugs, devices, diagnostics, and digital health.
This data is particularly relevant to long-term conditions such as diabetes mellitus, where drugs, lifestyle interventions, and digital technologies often work together.
Ready aims to combine real-world data and randomised controlled trials to improve efficacy, safety, and value for money of technologies to prevent and treat diabetes.
In order to achieve this, REDDIE will recreate randomised controlled trials within the real-world databases by first defining a typical target parameter and then looking for all people exposed to the same intervention in four European real-world databases.
Due to the large amount of real-world data available, results will be much faster and tested in a much bigger cohort than would ever be possible with randomised controlled trials.
Ready aims to maximise Europe’s scientific expertise and know-how to benefit people with diabetes by developing standards, guidance, and conducting assessments of the efficacy to effectiveness gap, resulting in safer, more efficient, and cost-effective interventions while enhancing the utilisation of real-world data in diabetes for regulatory decision-making.
Mike was diagnosed with type 1 diabetes at the age of 10.
Since then, he has learned to manage his condition through careful monitoring of his devices and wearables; But, what would happen if Mike’s data could be used to help researchers understand and learn more about diabetes?
What impact could his data have on other individuals living with diabetes?
Randomised controlled trials are the cornerstone of evidence-based medicine.
At the same time, the digitisation of real-world data from devices, and electronic health records provides opportunities to demonstrate efficacy and safety of innovative technologies including drugs, devices, diagnostics, and digital health.
This data is particularly relevant to long-term conditions such as diabetes mellitus, where drugs, lifestyle interventions, and digital technologies often work together.
Ready aims to combine real-world data and randomised controlled trials to improve efficacy, safety, and value for money of technologies to prevent and treat diabetes.
In order to achieve this, REDDIE will recreate randomised controlled trials within the real-world databases by first defining a typical target parameter and then looking for all people exposed to the same intervention in four European real-world databases.
Due to the large amount of real-world data available, results will be much faster and tested in a much bigger cohort than would ever be possible with randomised controlled trials.
Ready aims to maximise Europe’s scientific expertise and know-how to benefit people with diabetes by developing standards, guidance, and conducting assessments of the efficacy to effectiveness gap, resulting in safer, more efficient, and cost-effective interventions while enhancing the utilisation of real-world data in diabetes for regulatory decision-making.










